DaVita (DVA) Tops Q1 EPS by 29c; Raises Outlook

DaVita (NYSE: DVA) reported Q1 EPS of $2.09, $0.29 better than the analyst estimate of $1.80. Revenue for the quarter came in at $2.82 billion versus the consensus estimate of $2.82 billion.

"We have made incredible progress in our efforts to combat the pandemic," said Javier Rodriguez, CEO of DaVita. "To date almost three fourths of our U.S. dialysis patients have received at least one dose of the COVID-19 vaccine, thanks in large part to having obtained direct allocation of vaccines from the Federal and State governments, as well as the continued dedication of our front-line, caregiving teammates. Our focus on vaccinating our patients helped improve health equity among our patient population at the same time as reducing the risk to patients and teammates."

GUIDANCE:

DaVita sees FY2021 EPS of $8.20-$9.00, versus the consensus of $8.25.

For earnings history and earnings-related data on DaVita (DVA) click here.

You May Also Be Interested In

• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• Schlumberger Ltd. (SLB) Reports In-Line Q1 EPS
• P&G lifts annual profit forecast on strong US consumer demand, easing costs